Literature DB >> 20965806

Lactobacillus paracasei CNCM I-2116 (ST11) inhibits substance P-induced skin inflammation and accelerates skin barrier function recovery in vitro.

Audrey Gueniche1, Jalil Benyacoub, David Philippe, Philippe Bastien, Nicole Kusy, Lionel Breton, Stephanie Blum, Isabelle Castiel-Higounenc.   

Abstract

Over the past few decades the number of people presenting reactive skin has increased in industrial countries. Skin inflammation mediated by neuropeptides and impaired skin barrier function are both underlying features of reactive skin conditions. Live microorganisms defined as probiotics have been successfully used to improve health status in humans. Beyond the effects on intestinal microbiota, some probiotic strains display potent immune-modulatory properties at the skin level. The aim of this study was to evaluate whether Lactobacillus paracasei CNCM-I 2116 (ST11) could modulate reactive skin-associated inflammatory mechanisms. The Caco-2/PBMC co-culture cell system was stimulated on the apical side with probiotics. The resulting medium collected from the basolateral compartment of the cell culture system, so called conditioned medium, was tested in ex vivo human abdominal plastic skin explant models of substance P-induced skin inflammation and skin barrier reconstruction. We show that ST11 was able to abrogate vasodilation, edema, mast cell degranulation and TNF-alpha release induced by substance P, compared to control. Moreover, using ex vivo skin organ culture, we show that ST11-conditioned medium induced a significantly faster barrier function recovery after SLS disruption, compared to control. These results support a beneficial role of ST11 on key biological processes associated with barrier function and skin reactivity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20965806     DOI: 10.1684/ejd.2010.1108

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  18 in total

Review 1.  Skin microbiome and mast cells.

Authors:  Satomi Igawa; Anna Di Nardo
Journal:  Transl Res       Date:  2017-03-23       Impact factor: 7.012

2.  Synergistic Effect of Biogenics Derived from Potential Probiotics Together with Zingerone Against Biofilm Formation by Pseudomonas aeruginosa PAO1.

Authors:  Swati Chandla; Kusum Harjai; Geeta Shukla
Journal:  Probiotics Antimicrob Proteins       Date:  2021-03-30       Impact factor: 4.609

Review 3.  Rosacea and Diet: What is New in 2021?

Authors:  Tamara Searle; Faisal R Ali; Sarah Carolides; Firas Al-Niaimi
Journal:  J Clin Aesthet Dermatol       Date:  2021-12

4.  Acne vulgaris, probiotics and the gut-brain-skin axis - back to the future?

Authors:  Whitney P Bowe; Alan C Logan
Journal:  Gut Pathog       Date:  2011-01-31       Impact factor: 4.181

5.  Effects of oral intake of heat-killed Lactobacillus brevis SBC8803 (SBL88™) on dry skin conditions: A randomized, double-blind, placebo-controlled study.

Authors:  Masahiro Ogawa; Asako Saiki; Yuuta Matsui; Norihiko Tsuchimoto; Yasukazu Nakakita; Yoshihiro Takata; Takeshi Nakamura
Journal:  Exp Ther Med       Date:  2016-11-02       Impact factor: 2.447

Review 6.  The effect of probiotics on immune regulation, acne, and photoaging.

Authors:  Mary-Margaret Kober; Whitney P Bowe
Journal:  Int J Womens Dermatol       Date:  2015-04-06

Review 7.  Potential Role of the Microbiome in Acne: A Comprehensive Review.

Authors:  Young Bok Lee; Eun Jung Byun; Hei Sung Kim
Journal:  J Clin Med       Date:  2019-07-07       Impact factor: 4.241

Review 8.  Diet and rosacea: the role of dietary change in the management of rosacea.

Authors:  Emma Weiss; Rajani Katta
Journal:  Dermatol Pract Concept       Date:  2017-10-31

Review 9.  Atopic dermatitis and the intestinal microbiota in humans and dogs.

Authors:  J Mark Craig
Journal:  Vet Med Sci       Date:  2016-02-23

Review 10.  The Gut Microbiome as a Major Regulator of the Gut-Skin Axis.

Authors:  Iman Salem; Amy Ramser; Nancy Isham; Mahmoud A Ghannoum
Journal:  Front Microbiol       Date:  2018-07-10       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.